(NP (NP Expression/NN) (PP of/IN (NP 1,25-LRB-OH-RRB-2D3/NN receptors/NNS)) (PP on/IN (NP (NP alveolar/JJ lymphocytes/NNS) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP pulmonary/JJ granulomatous/JJ diseases/NNS)))))) ./.)
(S (NP-SBJ-41 1,25-LRB-OH-RRB-2D3/NN) (VP is/VBZ (VP known/VBN (S (NP-SBJ-42 *-41/-NONE-) (VP to/TO (VP be/VB (VP produced/VBN (NP *-42/-NONE-) (PP at/IN (NP (NP sites/NNS) (PP of/IN (NP granulomatous/JJ reactions/NNS)))))))))) ./.)
(S (SBAR-ADV In/IN order/NN to/TO (S (NP-SBJ-44 *-43/-NONE-) (VP characterize/VB (NP (NP the/DT cell/NN types/NNS) (SBAR (WHNP-45 that/WDT) (S (NP-SBJ *T*-45/-NONE-) (VP are/VBP (NP-PRD (NP targets/NNS) (PP for/IN (NP this/DT immunoregulatory/JJ hormone/NN)))))))))) ,/, (NP-SBJ-43 we/PRP) (VP have/VBP (VP evaluated/VBN (NP (NP the/DT expression/NN) (PP of/IN (NP 1,25-LRB-OH-RRB-2D3/NN receptors/NNS)) (PP on/IN (NP-COOD (NP peripheral/JJ blood/NN T-lymphocytes/NNS) and/CC (NP (NP those/DT) (VP recovered/VBN (NP */-NONE-) (PP from/IN (NP the/DT lung/NN)) (PP by/IN (NP (NP bronchoalveolar/JJ lavage/NN) (PP-COOD (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP (NP pulmonary/JJ granulomatous/JJ diseases/NNS) (PRN -LRB-/-LRB- (NP-COOD (NP tuberculosis/NN) and/CC (NP sarcoidosis/NN)) -RRB-/-RRB-))))) and/CC (PP from/IN (NP normal/JJ control/NN subjects/NNS))))) (S (NP-SBJ */-NONE-) (VP using/VBG (NP combined/JJ (ADJP-COOD (ADJP autoradiographic/JJ) and/CC (ADJP immunohistochemical/JJ)) techniques/NNS)))))))))) ./.)
(S (NP-SBJ-COOD (NP (NP Lavage/NN T-lymphocytes/NNS) (PP from/IN (NP (NP patients/NNS) (PP-COOD (PP with/IN (NP tuberculosis/NN)) or/CC (PP with/IN (NP sarcoidosis/NN)))))) ,/, (CONJP but/CC not/RB) (NP (NP those/DT) (PP from/IN (NP normal/JJ control/NN subjects/NNS))) ,/,) (VP expressed/VBD (NP 1,25-LRB-OH-RRB-2D3/NN receptors/NNS) (SBAR as/IN (S (NP-SBJ-46 */-NONE-) (VP demonstrated/VBN (NP *-46/-NONE-) (PP by/IN (NP-LGS (NP (NP binding/NN) (PP of/IN (NP -LCB-3H-RCB-1,25-LRB-OH-RRB-2D3/NN))) ,/, (SBAR (WHNP-47 which/WDT) (S (NP-SBJ-48 *T*-47/-NONE-) (VP was/VBD (VP inhibited/VBN (NP *-48/-NONE-) (PP-COOD (PP by/IN (NP-LGS (NP the/DT presence/NN) (PP of/IN (NP excess/JJ unlabeled/JJ 1,25-LRB-OH-RRB-2D3/NN)))) ,/, but/CC (PP not/RB by/IN (NP-LGS (NP the/DT presence/NN) (PP of/IN (NP unlabeled/JJ 25-LRB-OH-RRB-D3/NN))))))))))) (PRN -LRB-/-LRB- (NP (NP receptor-positive/JJ lymphocytes/NNS) :/: (NP-COOD (NP (NP sarcoidosis/NN) ,/, (FRAG (NP (QP 20/CD +\/-/CC 12/CD) %/NN))) ;/: (NP (NP tuberculosis/NN) ,/, (FRAG (NP (QP 31/CD +\/-/CC 17/CD) %/NN))))) -RRB-/-RRB-))))) ./.)
(S (PP In/IN (NP contrast/NN)) ,/, (NP-SBJ (NP blood/NN lymphocytes/NNS) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP granulomatous/JJ diseases/NNS))))) (VP did/VBD not/RB (VP express/VB (NP detectable/JJ 1,25-LRB-OH-RRB-2D3/NN receptors/NNS))) ./.)
(S (NP-SBJ (NP The/DT percentage/NN) (PP of/IN (NP (NP lavage/NN T-lymphocytes/NNS) (VP expressing/VBG (NP 1,25-LRB-OH-RRB-2D3/NN receptors/NNS))))) (VP was/VBD (ADJP-PRD (ADJP significantly/RB greater/JJR) (PP *ICH*-105/-NONE-)) (PP for/IN (NP (NP patients/NNS) (PP with/IN (NP tuberculosis/NN)) (VP presenting/VBG (PP with/IN (NP isolated/VBN hilar/JJ adenopathy/JJ))))) (PP-105 than/IN (FRAG (PP for/IN (NP (NP patients/NNS) (PP with/IN (NP pulmonary/JJ (NP-COOD (NP infiltrates/NNS) and\/or/CC (NP cavities/NNS))))))))) ./.)
(S-COOD (S (NP-SBJ-49 1,25-LRB-OH-RRB-2D3/NN receptors/NNS) (VP were/VBD (VP expressed/VBN (NP *-49/-NONE-) (PP to/TO (NP (NP a/DT greater/JJR extent/NN) (PP *ICH*-106/-NONE-))) (PP on/IN (NP CD8+/JJ T-lymphocytes/NNS)) (PP-106 than/IN (FRAG (PP on/IN (NP CD4+/JJ T-lymphocytes/NNS)))) (PP in/IN (NP sarcoidosis/NN))))) ,/, whereas/IN (S (NP-SBJ (NP (NP (NP a/DT greater/JJR proportion/NN) (PP of/IN (NP CD4+/JJ (NP *RNR*-50/-NONE-)))) (PP than/IN (FRAG (PP of/IN (NP CD8+/JJ (NP *RNR*-50/-NONE-))))) (NP-50 T-lymphocytes/NNS)) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP tuberculosis/NN))))) (VP were/VBD (ADJP-PRD receptor-positive/JJ))) ./.)
(S-COOD (S (NP-SBJ These/DT findings/NNS) (VP support/VBP (NP the/DT conclusion/NN (SBAR that/IN (S (NP-SBJ (NP the/DT interaction/NN) (PP of/IN (NP 1,25-LRB-OH-RRB-2D3/NN)) (PP with/IN (NP (NP its/PRP$ receptor/NN) (PP on/IN (NP T-lymphocytes/NNS))))) (VP may/MD (VP play/VB (NP an/DT important/JJ role/NN) (PP in/IN (NP (NP the/DT regulation/NN) (PP of/IN (NP granulomatous/JJ reactions/NNS))))))))))) ,/, but/CC (S (SBAR-ADV because/IN (S (NP-SBJ-51 these/DT receptors/NNS) (VP are/VBP (VP expressed/VBN (NP *-51/-NONE-) (PP on/IN (NP different/JJ lymphocyte/NN populations/NNS)))))) ,/, (NP-SBJ (NP the/DT net/JJ effect/NN) (PP of/IN (NP this/DT potent/JJ immunoregulatory/JJ molecule/NN))) (VP is/VBZ (ADJP-PRD likely/RB different/JJ) (PP in/IN (NP-COOD (NP sarcoidosis/NN) and/CC (NP tuberculosis/NN))))) ./.)
